BioSpace News Archive

Cellular Biomedicine Group, Inc. (Nasdaq: CBMG) (“CBMG” or the “Company”), a biopharmaceutical firm engaged in the drug development of immunotherapies for cancer and stem cell therapies for degenerative diseases, today reported its financial results and business highlights for the second quarter and six months ended June 30, 2020.

- Initiates Phase 1b/2a clinical trial with a proprietary long-acting GLP-1 agonist, in short bowel syndrome; first patients dosed in July and top-line data expected by Q1 2021 - - Amended definition of primary endpoint for Phase 3 trial with larazotide in celiac disease, allowing reduction in participants from 630 to 525 while maintaining statistical powering at 90% -

Quest Diagnostics Incorporated (NYSE: DGX), the world’s leading provider of diagnostic information services, today released its Annual Environmental, Social & Governance Report for 2019.

SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a clinical-stage biopharmaceutical company focused on developing life-changing medicines for patients with severe rare diseases and cancer, today reported second quarter financial results for the period ended June 30, 2020 and provided an update on recent company developments.

Thermo Fisher Scientific Inc. (NYSE:TMO), the world leader in serving science, has committed to supporting the efforts of historically black colleges and universities (HBCUs) in the U.S. to make COVID-19 testing available to all returning students, faculty and staff at the beginning of the fall semester.

Cipher Pharmaceuticals Inc. (TSX: CPH) (“Cipher” or “the Company”) today announced its financial and operating results for the three and six months ended June 30, 2020

Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a biotechnology company developing the next generation of immuno-oncology therapeutics based on its proprietary self-delivering RNAi (INTASYL™) therapeutic platform, today reported its financial results for the quarter ended June 30, 2020 and provided a business update.

Titan Medical Inc. (“Titan” or the “Company”) (TSX: TMD) (Nasdaq: TMDI), a medical device company focused on the design and development of single-port robotic surgical technologies, announces financial results for the three and six months ended June 30, 2020.

AbbVie (NYSE: ABBV) today announced the publication of results from the Phase 3 VIALE-A clinical study in patients with AML in the New England Journal of Medicine (NEJM). T

Cipher Pharmaceuticals Inc. (TSX: CPH) (“Cipher” or the “Company”) announced today that it has filed, and the Toronto Stock Exchange (the “TSX”) has accepted, a Notice of Intention to Make a Normal Course Issuer Bid (the “Notice”).